Volume 30, No 12, Dec 2020

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 30 Issue 12, December 2020: 1059-1060

RESEARCH HIGHLIGHTS

The SARS-CoV-2 spike protein: balancing stability and infectivity

Imre Berger^1,2,3,4 , Christiane Schaffitzel^1,2,*

¹School of Biochemistry, University of Bristol, 1 Tankard’s Close, Bristol BS8 1TD, UK
²Bristol Synthetic Biology Centre BrisSynBio, 24 Tyndall Ave, Bristol BS8 1TQ, UK
³Max Planck Bristol Centre for Minimal Biology, Cantock’s Close, Bristol BS8 1TS, UK
⁴School of Chemistry, University of Bristol, Cantock’s Close, Bristol BS8 1TS, UK
Correspondence: Christiane Schaffitzel(cb14941@bristol.ac.uk)

SARS-CoV-2 spike (S) glycoprotein is the key target of current vaccine development efforts to combat COVID-19; neutralizing antibodies bind S and interfere with S binding to its receptor, angiotensin-converting enzyme 2. Recent work reveals the molecular basis of increased infectivity of the globally prevailing D614G S mutation.

https://doi.org/10.1038/s41422-020-00430-4

FULL TEXT | PDF

Browse 746